Sichuan Biokin Pharmaceutical Co.,Ltd. (SHA:688506)
271.48
+2.10 (0.78%)
At close: Mar 20, 2026
SHA:688506 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | - | 3,220 | 403.96 | 1,005 | 154.22 |
Short-Term Investments | - | 2,533 | - | - | - |
Cash & Short-Term Investments | 6,157 | 5,753 | 403.96 | 1,005 | 154.22 |
Cash Growth | 7.02% | 1324.16% | -59.79% | 551.49% | -36.99% |
Accounts Receivable | - | 138.71 | 137.85 | 267.92 | 134.95 |
Other Receivables | - | 34.33 | 3.9 | 5.14 | 2.95 |
Receivables | - | 173.05 | 141.75 | 273.06 | 137.9 |
Inventory | - | 162.19 | 140.91 | 101.33 | 82.33 |
Other Current Assets | - | 218.87 | 89.2 | 47.22 | 49.36 |
Total Current Assets | - | 6,307 | 775.82 | 1,426 | 423.81 |
Property, Plant & Equipment | - | 573.09 | 534.79 | 420.26 | 404.98 |
Other Intangible Assets | - | 26.68 | 28 | 29.53 | 31.16 |
Long-Term Deferred Tax Assets | - | 179.2 | 76.18 | 83.23 | 65.8 |
Long-Term Deferred Charges | - | 18.4 | 1.82 | 1.79 | 1.16 |
Other Long-Term Assets | - | 32.79 | 8.5 | 30.28 | 24.54 |
Total Assets | - | 7,137 | 1,425 | 1,991 | 951.46 |
Accounts Payable | - | 219.25 | 160.17 | 128.85 | 45.96 |
Accrued Expenses | - | 437.25 | 257.88 | 244.81 | 139.81 |
Short-Term Debt | - | 595.5 | 275.12 | 155.13 | 161.23 |
Current Portion of Long-Term Debt | - | 235.28 | 174.37 | 30.47 | 0.02 |
Current Portion of Leases | - | 20.19 | 46.13 | 68.82 | 24.23 |
Current Income Taxes Payable | - | 14.13 | 0.01 | 4.96 | 1.54 |
Current Unearned Revenue | - | 356.13 | 8.67 | 17.42 | 10.78 |
Other Current Liabilities | - | 102.21 | 131.48 | 86.74 | 87.75 |
Total Current Liabilities | - | 1,980 | 1,054 | 737.2 | 471.32 |
Long-Term Debt | - | 1,189 | 183.92 | 239.96 | 50 |
Long-Term Leases | - | 28.13 | 8.65 | 52.95 | 51.42 |
Long-Term Unearned Revenue | - | 42.27 | 15.63 | 13.29 | 31.04 |
Long-Term Deferred Tax Liabilities | - | 1.94 | - | 0.08 | - |
Other Long-Term Liabilities | - | 9.73 | 11.19 | 14.05 | 15.81 |
Total Liabilities | - | 3,251 | 1,273 | 1,058 | 619.61 |
Common Stock | - | 401 | 401 | 401 | 360.9 |
Additional Paid-In Capital | - | 885.84 | 858.69 | 858.55 | 14.17 |
Retained Earnings | - | 2,599 | -1,109 | -328.45 | -45.98 |
Comprehensive Income & Other | - | 0.53 | 1.13 | 2.79 | 2.76 |
Total Common Equity | 7,171 | 3,886 | 151.87 | 933.89 | 331.85 |
Shareholders' Equity | 7,171 | 3,886 | 151.87 | 933.89 | 331.85 |
Total Liabilities & Equity | - | 7,137 | 1,425 | 1,991 | 951.46 |
Total Debt | 3,771 | 2,069 | 688.19 | 547.33 | 286.91 |
Net Cash (Debt) | 2,386 | 3,685 | -284.23 | 457.41 | -132.69 |
Net Cash Growth | -35.24% | - | - | - | - |
Net Cash Per Share | 5.77 | 9.19 | -0.71 | 1.26 | -0.37 |
Filing Date Shares Outstanding | 412.87 | 401 | 401 | 401 | 360.9 |
Total Common Shares Outstanding | 412.87 | 401 | 401 | 401 | 360.9 |
Working Capital | - | 4,327 | -278.01 | 689.14 | -47.51 |
Book Value Per Share | 17.37 | 9.69 | 0.38 | 2.33 | 0.92 |
Tangible Book Value | 7,142 | 3,859 | 123.88 | 904.36 | 300.69 |
Tangible Book Value Per Share | 17.30 | 9.62 | 0.31 | 2.26 | 0.83 |
Buildings | - | 325.3 | 304.56 | 302.23 | 300.82 |
Machinery | - | 640.12 | 554.25 | 439.83 | 419.75 |
Construction In Progress | - | 35.51 | 81.37 | 67.21 | 18.18 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.